Protagenic Therapeutics Inc (PTIXW)
Official siteBIOTECHNOLOGY
Last updated: Apr 24, 2026 at 5:00 PM ET
Protagenic Therapeutics Inc (PTIXW) Financials: Revenue, Profit and Cash Flow
For the fiscal year ended Dec 31, 2025, net income was -$5.16M, operating cash flow was -$4.14M and free cash flow was -$4.14M. The quarter ended Dec 31, 2025 had net income of $2.21M.
Revenue and Margins
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | N/A | N/A | N/A | N/A | N/A |
| Dec 2024 | $0 | N/A | N/A | N/A | N/A |
| Dec 2023 | $0 | N/A | N/A | N/A | N/A |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
| Dec 2021 | $0 | N/A | N/A | N/A | N/A |
| Dec 2020 | $0 | N/A | N/A | N/A | N/A |
| Dec 2019 | $0 | N/A | N/A | N/A | N/A |
| Dec 2018 | $0 | N/A | N/A | N/A | N/A |
| Dec 2017 | $0 | N/A | N/A | N/A | N/A |
| Dec 2016 | N/A | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Dec 2025, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cost of revenue | $37.72K | $50.29K | $28.22K | $30 | N/A | $286 | $339 | $347 | $148 | $534 |
| Gross profit | -$37.72K | -$50.29K | -$28.22K | -$30 | N/A | -$286 | -$339 | -$347 | -$148 | -$534 |
| Research and development | $1.70M | $3.85M | $3.32M | $1.59M | $1.14M | $699.80K | $807.95K | $881.19K | $717.45K | $417.87K |
| Operating income | -$5.83M | -$5.70M | -$4.53M | -$3.56M | -$4.14M | -$2.55M | -$2.09M | -$2.31M | -$2.37M | -$2.23M |
| Net income | -$5.16M | -$5.53M | -$5.00M | -$3.56M | -$4.52M | -$2.55M | -$1.75M | -$2.56M | -$2.26M | -$2.28M |
| EBITDA | N/A | -$5.47M | -$4.50M | -$3.42M | -$4.14M | -$2.55M | -$2.09M | -$2.31M | -$2.37M | N/A |
Quarterly
| Line item | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $0 | $0 | $0 | -$25.14K | $25.14K | $0 | $3.20K | $0 | $0 | $0 | $0 |
| Gross profit | N/A | -$12.57K | -$12.57K | -$12.57K | -$50.29K | -$12.57K | -$12.57K | -$12.57K | N/A | -$1.42K | -$91 | -$30 |
| Operating income | -$925.10K | -$1.11M | -$2.34M | -$1.45M | -$1.64M | -$652.00K | -$1.67M | -$1.74M | -$1.21M | -$1.43M | -$1.14M | -$739.00K |
| Net income | $2.21M | -$869.50K | -$5.06M | -$1.44M | -$1.55M | -$641.00K | -$1.61M | -$1.72M | -$1.68M | -$1.40M | -$1.21M | -$718.00K |
Balance Sheet
As of Dec 2025, short-term debt of $3.16M exceeded cash and equivalents by $943.26K. Shareholder equity was negative, at -$4.69M, as total liabilities of $6.82M exceeded total assets of $2.13M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $2.13M | $1.96M | $4.32M | $8.04M | $11.06M | $879.25K | $842.27K | $696.88K | $1.78M | $3.16M |
| Current assets | $2.30M | $1.88M | $4.20M | $8.04M | $11.06M | $879.25K | $841.98K | $696.27K | $1.78M | $3.16M |
| Cash and equivalents | $2.21M | $1.84M | $1.29M | $215.19K | $541.17K | $671.09K | $798.62K | $362.49K | $399.69K | $3.10M |
| Total liabilities | $6.82M | $942.76K | $655.25K | $1.12M | $1.12M | $2.03M | $1.48M | $907.77K | $561.69K | $684.86K |
| Short-term debt | $3.16M | N/A | N/A | $344.23K | $186.15K | N/A | N/A | N/A | N/A | N/A |
| Long-term debt | N/A | N/A | N/A | N/A | $318.43K | $1.37M | $279.37K | N/A | N/A | N/A |
| Shareholder equity | -$4.69M | $1.01M | $3.67M | $6.92M | $9.94M | -$1.15M | -$634.37K | -$210.88K | $1.22M | $2.48M |
Quarterly
| Line item | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $2.13M | $2.14M | $6.49M | $988.65K | $1.96M | $1.51M | $1.47M | $2.58M | $4.32M | $5.43M | $6.92M | $7.67M |
| Total liabilities | $6.82M | $9.70M | $10.46M | $1.08M | $942.76K | $789.32K | $674.56K | $446.10K | $655.25K | $1.28M | $1.51M | $1.25M |
| Cash and equivalents | $2.21M | $2.72M | $4.10M | $872.96K | $1.84M | $1.06M | $924.60K | $831.78K | $1.29M | $153.33K | $219.44K | $138.49K |
| Shareholder equity | -$4.69M | -$4.70M | -$3.97M | -$88.33K | $1.01M | $719.01K | $792.52K | $2.13M | $3.67M | $4.15M | $5.41M | $6.41M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.14M | -$4.22M | -$3.70M | -$1.99M | -$2.80M | -$1.35M | -$487.99K | -$1.07M | -$1.38M | -$1.14M |
| Capital expenditures | $3 | $0 | $149.78K | $1.80K | $4 | $0 | $0 | $0 | $0 | $0 |
| Free cash flow | -$4.14M | -$4.22M | -$3.85M | -$2.00M | -$2.80M | -$1.35M | -$487.99K | -$1.07M | -$1.38M | -$1.14M |
| Investing cash flow | $943.18K | $2.80M | $4.78M | $1.60M | -$9.91M | N/A | $250.00K | $1.05M | -$1.29M | N/A |
| Financing cash flow | $4.51M | $1.96M | $0 | $0 | $12.58M | $1.22M | $670.00K | N/A | $0 | $4.28M |
Quarterly
| Line item | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$410.42K | -$1.49M | -$1.17M | -$1.07M | -$819.79K | -$185.66K | -$1.55M | -$1.66M | -$1.14M | -$655.77K | -$1.53M | -$371.83K |
| Capital expenditures | $6 | $3 | $3 | $3 | $0 | $0 | $0 | $5 | $93.97K | $55.81K | $0 | $1.80K |
| Free cash flow | -$410.43K | -$1.49M | -$1.17M | -$1.07M | -$819.79K | -$185.66K | -$1.55M | -$1.66M | -$1.24M | -$711.57K | -$1.53M | -$373.64K |
Frequently Asked Questions About PTIXW
Is Protagenic Therapeutics profitable?
No. Protagenic Therapeutics reported net income of -$5.16M for the fiscal year ended Dec 31, 2025.
How much free cash flow does PTIXW generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$4.14M minus capital expenditures of $3 produced free cash flow of -$4.14M.
How much debt does Protagenic Therapeutics have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $3.16M and cash and equivalents of $2.21M.
PTIXW pages: Overview, Financials